Reuters logo
BRIEF-Minerva announces completion of bridging study to select improved formulation of MIN-101 for use in phase 3 trial for the treatment of negative symptoms in patients with schizophrenia
June 22, 2017 / 12:53 PM / 4 months ago

BRIEF-Minerva announces completion of bridging study to select improved formulation of MIN-101 for use in phase 3 trial for the treatment of negative symptoms in patients with schizophrenia

June 22 (Reuters) - Minerva Neurosciences Inc

* Minerva announces completion of bridging study to select improved formulation of MIN-101 for use in phase 3 trial for the treatment of negative symptoms in patients with schizophrenia

* Minerva Neurosciences Inc - Company to proceed with initiation of phase 3 trial on schedule in second half of 2017 for MIN-101

* Minerva Neurosciences Inc - Company plans to immediately initiate cmc scale-up processes that will form part of NDA in future

* Minerva Neurosciences - Plans to use selected formulation in upcoming phase 3 clinical trial, which remains on schedule for initiation H2 of 2017

* Minerva Neurosciences - Filed patent application for GR formulation, which is in addition to already granted patent in U.S. provides protection until 2035

* Minerva Neurosciences Inc - Plans to use selected formulation in upcoming phase 3 clinical trial for potential future submission of NDA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below